United Statesglaxosmithkline.com
TESARO, Inc. is a U.S. biopharmaceutical company focused on oncology therapeutics and supportive care. Founded in 2010 and based in Waltham, Massachusetts, the company was acquired by GlaxoSmithKline (GSK) in 2019.
TESARO developed niraparib (marketed as Zejula), an oral poly(ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain ovarian cancers, and rolapitant (Varubi), a neurokinin-1 (NK1) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The company also advanced the anti-PD-1 antibody dostarlimab (now marketed by GSK as Jemperli) within its immuno-oncology pipeline.
TESARO’s programs helped expand targeted oncology options and supportive care therapies, which are now managed within GSK’s oncology portfolio.
FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.
